









Markets
/
Stocks
/
nasdaq-eypt
/

EyePoint Pharmaceuticals Inc

EYPT

13.300USD

+0.570+4.48%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

925.28MMarket Cap

LossP/E TTM



EyePoint Pharmaceuticals Inc

13.300

+0.570+4.48%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of EyePoint Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

EyePoint Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 71 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 36.08.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

EyePoint Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

71 / 159

Overall Ranking

186 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

EyePoint Pharmaceuticals Inc Highlights

StrengthsRisks

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.

Growing

The company is in a growing phase, with the latest annual income totaling USD 43.27M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 43.27M.

Fairly Valued

The company’s latest PE is -4.43, at a medium 3-year percentile range.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 1.03K shares of this stock.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

36.083

Target Price

+192.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of EyePoint Pharmaceuticals Inc is 6.12, ranking 148 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 966.00K, representing a year-over-year decrease of 90.82%, while its net profit experienced a year-over-year decrease of 103.44%.

Score

Industry at a Glance

Previous score

6.12

Change



Financials

8.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.65

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

EyePoint Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of EyePoint Pharmaceuticals Inc is 6.10, ranking 134 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -4.43, which is -81.22% below the recent high of -0.83 and -268.57% above the recent low of -16.33.

Score

Industry at a Glance

Previous score

6.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 71/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of EyePoint Pharmaceuticals Inc is 8.67, ranking 13 out of 159 in the Pharmaceuticals industry. The average price target is 33.00, with a high of 50.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

36.083

Target Price

+171.30%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

EyePoint Pharmaceuticals Inc

EYPT

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of EyePoint Pharmaceuticals Inc is 6.97, ranking 92 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 16.57 and the support level at 11.07, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.79

Change

0.18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.551

Sell

RSI(14)

37.398

Neutral

STOCH(KDJ)(9,3,3)

21.578

Buy

ATR(14)

1.023

Low Volatility

CCI(14)

-76.517

Neutral

Williams %R

74.242

Sell

TRIX(12,20)

-0.919

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

12.890

Buy

MA10

13.902

Sell

MA20

14.827

Sell

MA50

16.008

Sell

MA100

14.402

Sell

MA200

11.881

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of EyePoint Pharmaceuticals Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 126.07%, representing a quarter-over-quarter decrease of 0.74%. The largest institutional shareholder is The Vanguard, holding a total of 4.82M shares, representing 5.82% of shares outstanding, with 4.96% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Cormorant Asset Management, LP

8.27M

-0.72%

Suvretta Capital Management, LLC

6.19M

-8.99%

Adage Capital Management, L.P.

5.56M

-18.24%

The Vanguard Group, Inc.

Star Investors

3.79M

-0.21%

BlackRock Institutional Trust Company, N.A.

4.28M

-6.88%

Franklin Advisers, Inc.

4.14M

-3.07%

Federated Hermes Global Investment Management Corp.

3.58M

-0.04%

TCG Crossover Management, LLC

3.57M

Citadel Advisors LLC

2.14M

-8.91%

Paradigm BioCapital Advisors LP

2.01M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of EyePoint Pharmaceuticals Inc is 4.82, ranking 82 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.80. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.